2023年HER-2阳性乳腺癌治疗进展

Advancement of HER-2 positive breast cancer treatment in 2023

HER-2阳性乳腺癌占所有乳腺癌的20%~25%,是一种具有侵袭性和高度恶性的亚型,预后较差。近年来,随着对HER-2阳性乳腺癌的生物学特征及其相关信号通路的深入了解,相关靶向药物和联合策略不断涌现并取得显著疗效。本文回顾了2023年HER-2阳性乳腺癌在早期和晚期治疗领域的热点研究进展,总结了脑转移患者中的治疗突破,并对未来可能改变临床实践的关键问题和研究方向进行了展望。

HER-2 positive breast cancer is an aggressive and highly malignant subtype accounting for 20%-25%of all breast cancer,with a poor prognosis.In recent years,with the in-depth understanding of biological characteristics of HER-2 positive breast cancer and its related signaling pathways,new targeted drugs have been developed and new strategies of combination therapies have brought encouraging outcomes.In this article,we reviews the research progress of HER-2 positive breast cancer in early and late stages in 2023,as well as therapeutic breakthroughs in patients with brain metastases,and then discusses key issues and research directions that may change clinical practice in the future.